Q4 2026 Tatva Chintan Pharma Chem Ltd Earnings Call Transcript
Key Points
- Tatva Chintan Pharma Chem Ltd (BOM:543321) reported a strong year-on-year revenue growth of 24% for Q4 FY26, reaching INR 1,341 million.
- EBITDA for the quarter increased significantly by 214% compared to the same period last year, driven by a better product mix and improved operating leverage.
- The Electrolyte Salts segment showed exceptional growth, with revenue increasing by 865% quarter-on-quarter and 1,378% year-on-year.
- The company successfully commercialized its new production block at the Dahej site, enhancing its operational capacity.
- Tatva Chintan Pharma Chem Ltd (BOM:543321) is optimistic about future growth, with plans to launch two agro intermediates with significant revenue potential once the new Jolva plant becomes operational.
- Phase Transfer Catalyst revenue declined by 20% year-on-year, despite an 11% sequential growth.
- The Pharma and Agro Intermediates and Specialty Chemicals segment saw a 24% sequential decline in revenue.
- The company faces challenges due to rising costs of raw materials, fuel, and packing materials, influenced by ongoing geopolitical conflicts.
- Freight rates have increased, adding to the company's operational costs.
- Despite the strong performance, the company remains cautious about future growth due to uncertainties in the geopolitical landscape, which could impact customer demand.
Ladies and gentlemen, good day, and welcome to the Tatva Chintan Pharma Chem Limited Q4 FY26 Earnings Conference Call hosted by ICICI Securities. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Sanjesh Jain from ICICI Securities. Thank you, and over to you, sir.
Thanks, Swapnali. Good evening, everyone. Thank you for joining on for Tatva Chintan Pharma Q4 FY26 Results Conference Call. We have Tatva Chintan management on call represented by Mr. Chintan Shah, Managing Director; Mr.
Ajesh Pillai, Chief Financial Officer. I would like to invite Ajeshji to initiate with opening remarks, post which we will have a Q&A session. Over to you, sir.
Thank you, Sanjeshji. Good evening, everyone, and welcome to Q4 FY '26 Earnings Call of Tatva Chintan Pharma Chem Limited. Our financial results for the quarter have already been submitted to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
